FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit
FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit
The company reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year.
Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25.
Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high
The shares of the company saw a spurt in volume by more than 2 times.
The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.
Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!
With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence
With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence
This Multibagger Pharma Stock Secures Strategic Foothold in Europe — Is It Set for Massive Growth?
Indian Pharma company breaks into European Market with High-Potential Product, Promising New Revenue Streams
Indian Pharma company breaks into European Market with High-Potential Product, Promising New Revenue Streams
Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why
The company has a market cap of over Rs 17,000 crore with a PE of 55x, an ROE of 27 per cent and an ROCE of 33 per cent.
The stock gave multibagger returns of 250 per cent in 1 year, 720 per cent in 3 years and a whopping 2,700 per cent in 5 years.
Multibagger Pharma Stock Hit 52-Week High As Board Announces Stock Split From Rs 5 to Rs 2 and Stellar Quarterly Results (Q2FY25) and Half-Yearly Results (H1FY25)
The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years.
The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years.
Multibagger Pharma Stock To Keep Under Radar As Board Likely To Announce Stock Split
The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years.
The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years.
Pharma Penny Stock At Rs 65 Enters Into An Mou With Vaibhav Kashinath Chaudhari & Mistycube Analytics To Enter French West African Market
The company has a market cap of Rs 76 crore and as of September 27, 2024, the stock is trading at Rs 65 per share on NSE.
The company has a market cap of Rs 76 crore and as of September 27, 2024, the stock is trading at Rs 65 per share on NSE.
Multibagger Pharma Company Recommends 1:1 Bonus Issue and 1:5 Stock Split; Expects to Continue its Strong Growth Momentum with Innovation
In July 2024, the promoters of the company bought 13,02,000 shares and increased their stake to 31.61 per cent compared to 26.32 per cent in June 2024.
From Rs 38.05 to Rs 187.25 per share, the stock gave multibagger returns of 393 per cent in 3 years.
Pharma stock under Rs 65 is in the green as Board allots 52,52,190 equity shares to non-promoters post-stock split!
From Rs 35.03 per share (52-week low) to Rs 60.09 per share, the stock is up by 71.5 per cent and gave multibagger returns of 110 per cent in 2 years.
From Rs 35.03 per share (52-week low) to Rs 60.09 per share, the stock is up by 71.5 per cent and gave multibagger returns of 110 per cent in 2 years.
Multibagger pharma stock under Rs 70 to keep under the radar as company announces positive quarterly results (Q1FY25)
From Rs 33.30 per share (52-week low) to Rs 63.79 per share, the stock is up by 91.6 per cent and gave multibagger returns of 156 per cent in 2 years.
From Rs 33.30 per share (52-week low) to Rs 63.79 per share, the stock is up by 91.6 per cent and gave multibagger returns of 156 per cent in 2 years.
Stock at Rs 130.05 from the pharmaceuticals industry hit upper circuit as Board announces 1:1 bonus share; Record date inside!
The company has a market cap of Rs 51.55 crore and stock is up by 66 per cent from its 52-week low of Rs 78 per share.
The company has a market cap of Rs 51.55 crore and stock is up by 66 per cent from its 52-week low of Rs 78 per share.